Krystal biotech, inc. (KRYS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating Activities
Net loss

-20,318

-19,088

-17,439

-15,922

-12,850

-10,889

-8,574

-11,093

-9,576

-7,920

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation

951

748

559

406

255

141

94

61

40

23

0

0

0

Stock-based compensation expense

1,465

1,239

1,218

1,218

1,040

792

548

323

220

246

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

3,263

0

0

0

(Increase) decrease in
Prepaid expenses and other current assets

431

891

832

321

555

321

229

136

268

77

0

0

0

Prepaid rent

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right-of-use asset, net

185

226

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

-538

-199

153

504

799

112

-9

-27

13

133

0

0

0

Accrued expenses and other current liabilities

656

547

854

971

877

644

88

470

336

442

0

0

0

Net cash used in operating activities

-21,725

-18,713

-15,185

-12,882

-10,291

-9,445

0

0

0

-

-

-

-

Investing Activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchases of property and equipment

6,200

6,399

0

0

0

-

-

-

-

210

0

0

0

Purchases of short-term investments

10,028

8,573

0

0

0

-

-

-

-

-

-

-

-

Proceeds from maturities of short-term investments

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of other noncurrent assets

-

-

-

-

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-3,791

-4,968

0

0

0

-

-

-

-

-

-

-

-

Financing Activities
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from the issuance of convertible promissory notes

-

-

-

-

-

-

-

-

-

1,299

0

0

0

Issuance of common stock, net

107,728

107,525

171,514

167,896

73,881

73,847

0

0

0

-

-

-

-

Net cash provided by financing activities

107,728

107,525

171,514

167,896

73,881

73,847

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Net decrease in cash and cash equivalents

82,212

83,844

148,139

144,774

50,785

54,079

-5,903

38,295

45,269

47,668

0

0

0

Supplemental Disclosures of Non-Cash Investing and Financing Activities
Unpaid purchases of property and equipment

1,608

681

0

0

0

-

-

-

-

-

-

-

-

Unpaid offering costs

0

-

-

0

0

-

-

-

-

-

-

-

-

Unpaid deferred offering costs

-

-

-

-

-

-

-

-

0

-

-

-

-

Initial recognition of right-of-use assets

-

-

-

-

0

-

-

-

-

-

-

-

-

Conversion of preferred units to preferred stock

-

-

-

-

-

-

-

-

-

-

-

0

0